Should busulfan-containing regimen be avoided for young female patients undergoing hematopoietic stem cell transplantation?

被引：8
作者：
Okuda, S. [1 ]
Sato, M. [1 ]
Terasako, K. [1 ]
Kako, S. [1 ]
Oshima, K. [1 ]
Kanda, Y. [1 ]
机构：
[1] Jichi Med Univ, Saitama Med Ctr, Div Hematol, Saitama, Japan
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 43卷 / 03期
关键词：
TOTAL-BODY IRRADIATION; BONE-MARROW-TRANSPLANTATION; MYELOID-LEUKEMIA; CYCLOPHOSPHAMIDE; DISEASE;
D O I：
10.1038/bmt.2008.309
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：261 / 262
页数：2
相关论文
共 9 条
[1]   Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation:: a meta-analysis [J].
Hartman, AR ;
Williams, S ;
Dillon, JJ .
BONE MARROW TRANSPLANTATION, 1998, 22 (05) :439-443
[2]   Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor [J].
Kanda, Y ;
Sakamaki, H ;
Sao, H ;
Okamoto, S ;
Kodera, Y ;
Tanosaki, R ;
Kasai, M ;
Hiraoka, A ;
Takahashi, S ;
Miyawaki, S ;
Kawase, T ;
Morishima, Y ;
Kato, S .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (11) :881-889
[3]   Successful pregnancy following busulfan and cyclophosphamide conditioning and allogeneic bone marrow transplantation for chronic myeloid leukemia [J].
Matias, Kleber ;
Matias, Carolina ;
Teixeira, Heberton ;
Freire, Ana Dulce ;
Azevedo, Alta .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (08) :944-945
[4]   Preservation of ovarian function by ovarian shielding when undergoing total body irradiation for hematopoietic stem cell transplantation: A report of two successful cases [J].
Nakagawa, K ;
Kanda, Y ;
Yamashita, H ;
Hosoi, Y ;
Oshima, K ;
Ohtomo, K ;
Ban, N ;
Yamakawa, S ;
Nakagawa, S ;
Chiba, S .
BONE MARROW TRANSPLANTATION, 2006, 37 (06) :583-587
[5]  
NAKAGAWA K, 2008, BONE MARROW IN PRESS
[6]   Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation:: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia [J].
Ringdén, O ;
Remberger, M ;
Ruutu, T ;
Nikoskelainen, J ;
Volin, L ;
Vindelov, L ;
Parkkali, T ;
Lenhoff, S ;
Sallerfors, B ;
Mellander, L ;
Ljungman, P ;
Jacobsen, N .
BLOOD, 1999, 93 (07) :2196-2201
[7]   Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis [J].
Scott, BL ;
Sandmaier, BM ;
Storer, B ;
Maris, MB ;
Sorror, ML ;
Maloney, DG ;
Chauncey, TR ;
Storb, R ;
Deeg, HJ .
LEUKEMIA, 2006, 20 (01) :128-135
[8]   Nonmalignant late effects after allogeneic stem cell transplantation [J].
Socié, G ;
Salooja, N ;
Cohen, A ;
Rovelli, A ;
Carreras, E ;
Locasciulli, A ;
Korthof, E ;
Weis, J ;
Levy, V ;
Tichelli, A .
BLOOD, 2003, 101 (09) :3373-3385
[9]   Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:: long-term follow-up of 4 randomized studies [J].
Socié, G ;
Clift, RA ;
Blaise, D ;
Devergie, A ;
Ringden, O ;
Martin, PJ ;
Remberger, M ;
Deeg, HJ ;
Ruutu, T ;
Michallet, M ;
Sullivan, KM ;
Chevret, S .
BLOOD, 2001, 98 (13) :3569-3574
1